Cymabay Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

CymaBay Therapeutics

14/05/2021 03:12

* Cymabay Therapeutics Inc  CBAY.OQ  reported a quarterly
adjusted loss of 25 cents​​ per share for the quarter ended
in March. The mean expectation of eight analysts for the quarter
was for a loss of 24 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Cymabay Therapeutics Inc's reported EPS for the quarter was a
loss of 25 cents​.
* The mean earnings estimate of analysts had fallen by
about 3.2% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Cymabay Therapeutics Inc shares had fallen by 5.5% this
quarter and lost 25.3% so far this year.
* The company reported a quarterly loss of $17.57 million.
* Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $12.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 14 at 02:12 a.m. GMT.
​All figures in US dollars